Honor Witness | Haibu Pharmaceu≈↑∑₽tical Awarded 'ADC New Infrastruct↓γε←ure Pioneer Enterprise'
Classification:
Company News
Release time:
2024-05-15
On April 18, the heavyweight brandλ£≤σ conference - "The First¶§ Future XDC New Drug Conf↔™erence" jointly creat₽♣♣♠ed by Tongxieyi and Chengdu Medi₩Ωcal City kicked off inΩσ≤∏ Chengdu Medical City.
The conference focused on thα♦λe theme of "Co-creating the Futu&re of the Conjugated Drug Industry", coε∏ncentrating on industrial re↓∞search ecology and grasping the wave o<↔σ©f technological change. Over 1,600 R≤£★&D experts, scholars, a↓∑ Ωnd production professionals from the ™₹industry provided authoritative technic♣ ★→al interpretation perspecΩ ∏tives and guidance for pharmaceγ∞←¶utical innovators. Meanwhil↔©e, the online live broadcast attractedγα more than 20,000 viewers.
Xieyi Evening Party
"The Sky of Bioconjugation"
At the evening party,↓← a list of pioneeringΩ✔★ε companies in ADC/nuclea>¶∏r drug innovation was™₹ released, with Haibu Pharmaceutical aw¶βΩεarded as an "ADC New Infrastructure ©∞Pioneer Company."
Haibu Pharmaceutical began its invo♦☆♦✘lvement in ADC small molecule R&amγ→✔p;D business in 2018δ∞. It currently has rich experienc ←αe in Linker design, selection a≈✘ nd design of Payloads, L₹αinker-antibody conjugation, and D≤÷∏AR control. Clients wi₽£→↓th needs are welcome to contact foαr discussions.
Service hotline: 010σ≠-67887110-8088
Email: diwei@hopelife.cn
Beijing Haibu Pharmaceutical Technolo™←gy Co., Ltd. (referred to as↔≥ "Haibu Pharmaceutical") was esta∞♠•blished in 2005 and is a high♣≤δ-tech enterprise with "chemical drug↓" R&D" as its core capability. It • has a Beijing R&D centβ∞er, an API and formulatiε↓ €on pilot verification center, and a GMP✔γσ♠ industrial production ba$®se. The company mainly eβ¥ngages in CRO services for&α < APIs and formulations, M ☆AH joint licensing, API-relπ¥©₩ated declarations, and commercial su♣♣λpply of pharmaceutical intermediates.₩βIt has rich experience in R&D tσ®♣¥ransfer production and regist ÷φration declaration fo•>≥r various dosage forms such as÷≠&≠ chemical APIs, oral solids, liquid α₩formulations, sterile injecti₹≤✔★ons, and external prepara∏→tions. The R&D pr☆✘∞∑oducts cover multiple indication area¥₹s including anti-tumor, ant₽☆↓i-depression, anti-epilepsy, anti-anxi✘→₽ety, cardiovascular diseases, d↕&β←igestive system diseases, respiratory ♣☆÷★system diseases.
Haibu Pharmaceutical has been awarded t∏×☆he title of "Top 20 Chinese Pharmaceut£&®Ωical R&D Companies" for many years ♠ consecutively and recognize♦↕&↕d as a "Specialized & In ∞novative Enterprise" by Beijing Muni€∑cipality; it is also designa×≤✔ted as a "National High-tech Enterprise¥", "Beijing Science & ↔>∞εTechnology Research Development Inst≠↔itution", and "Beijing Yizhuang E•☆εnterprise Innovation Center", among ot∞≈₹★hers.
Beijing Hope Pharmaceutic• δal Co., Ltd.
